TC BioPharm Files August 2025 6-K Report

Ticker: TCBWF · Form: 6-K · Filed: Aug 5, 2025 · CIK: 1872812

Sentiment: neutral

Topics: 6-K, regulatory-filing, biopharmaceutical

TL;DR

TC BioPharm filed its August 6-K, just standard company info.

AI Summary

TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on August 5, 2025. The filing is a report of a foreign private issuer for the month of August 2025. The company is incorporated in Scotland, United Kingdom, with its principal executive offices located at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR.

Why It Matters

This filing provides routine updates for investors regarding TC BioPharm's status as a foreign private issuer. It confirms their reporting obligations and basic company information.

Risk Assessment

Risk Level: low — This filing is a routine administrative report and does not contain significant new financial or operational information that would typically alter risk.

Key Players & Entities

FAQ

What type of filing is this for TC BioPharm?

This is a Form 6-K, a Report of Foreign Private Issuer.

When was this Form 6-K filed?

The filing was made on August 5, 2025.

Where are TC BioPharm's principal executive offices located?

The principal executive offices are located at Maxim 1, 2 Parklands Way, Holytown, Motherwell, ML1 4WR, Scotland, United Kingdom.

Does TC BioPharm file annual reports under Form 20-F or 40-F?

TC BioPharm indicated that it files annual reports under cover of Form 20-F.

What is the SIC code for TC BioPharm?

The Standard Industrial Classification (SIC) code for TC BioPharm is 2836, for Biological Products (no diagnostic substances).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on August 5, 2025 regarding TC BioPharm (Holdings) plc (TCBWF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing